|
[1] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.
|
|
[2] Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology:Hepatocllular carcinoma(2018.V1)[EB/OL]. http://www. csco. org. cn/cat/147/show/8627. html.(in Chinese)中国临床肿瘤学会．CSCO原发性肝癌诊疗指南(2018. V1)[EB/OL]. http://www. csco. org. cn/cat/147/show/8627.html.
|
|
[3] LI JJ,YANG Z,HUANG ZS. Progress in basic and clinical research on molecular targeted therapy for primary hepatic carcinoma[J]. World Chin J Dig,2019,27(10):643-650.(in Chinese)李建基，杨哲，黄赞松．原发性肝癌分子靶向治疗基础与临床研究进展[J]．世界华人消化杂志，2019,27(10):643-650.
|
|
[4] LLOVET JM,RICCI S,MAZZAFERRO V,et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390.
|
|
[5] CHENG AL,KANG YK,CHEN Z,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised,doubleblind,placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34.
|
|
[6] IKEDA K,KUDO M,KAWAZOE S,et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol,2017,52(4):512-519.
|
|
[7] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[8] WILHELM SM,DUMAS J,ADNANE L,et al. Regorafenib(BAY73-4506):A new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer,2011,129(1):245-255.
|
|
[9] BRUIX J,QIN S,MERLE P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):A randomised,double-blind,placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
|
|
[10] ABOU-ALFA GK,MEYER T,CHENG AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1):54-63.
|
|
[11] SPRATLIN JL,COHEN RB,EADENS M,et al. Phase I pharmacologic and biologic study of ramucirumab(IMC-1121B),a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2[J]. J Clin Oncol,2010,28(5):780-787.
|
|
[12] ZHU AX,PARK JO,RYOO BY,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH):A randomised,double-blind,multicentre,phase 3 trial[J]. Lancet Oncol,2015,16(7):859-870.
|
|
[13] ZHU AX,KANG YK,YEN CJ,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increasedα-fetoprotein concentrations(REACH-2):A randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol,2019,20(2):282-296.
|
|
[14] QIN S,BAI Y,LIM HY,et al. Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol,2013,31(28):3501-3508.
|
|
[15] QIN S,CHENG Y,LIANG J,et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma:A subgroup analysis of the EACH study[J]. Oncologist,2014,19(11):1169-1178.
|
|
[16] LU WQ,LE LY,TIAN BR,et al. Clinical trial of raltitrexed injection combined with oxaliplatin injection in the treatment of advanced primary liver cancer[J]. Chin J Clin Pharmacol,2019,35(2):102-105.(in Chinese)鲁文权，乐凌云，田炳如，等．雷替曲塞注射剂联合奥沙利铂注射剂治疗晚期原发性肝癌的临床研究[J]．中国临床药理学杂志，2019,35(2):102-105.
|
|
[17] YUAN Y,XU GH. Efficacy of XELOX protocol in treatment of advanced primary liver cancer and its effect on levels of serum tumor markersr[J]. Med Pharm J Chin PLA,2017,29(6):44-47.(in Chinese)袁云，徐国辉．XELOX方案治疗晚期原发性肝癌的效果及对血清肿瘤标志物水平的影响[J]．解放军医药杂志，2017,29(6):44-47.
|
|
[18] IWAI Y,ISHIDA M,TANAKA Y,et al. Involvement of PD-L1on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proc Natl Acad Sci U S A,2002,99(19):12293-12297.
|
|
[19] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
|
[20] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
|
|
[21] ZHANG C,WANG J. Experience in treating hepatocellular carcinoma by classical prescription[J]. J Changchun Univ Chin Med,2018,34(5):908-910.(in Chinese)张驰，王军．原发性肝细胞癌经方论治管见[J]．长春中医药大学学报，2018,34(5):908-910.
|
|
[22] ZHANG Y,ZHOU YF,HU M,et al. Research progress of traditional Chinese medicine for the invasion and metastasis of hepatocellular carcinoma[J]. Chin J Clin Pharmacol Ther,2017,22(5):594-600.(in Chinese)张颖，周媛凤，胡敏，等．肝癌侵袭转移的中医药研究进展[J]．中国临床药理学与治疗学，2017,22(5):594-600.
|
|
[23] CHEN XL,XU LT,WANG P,et al. Survival analysis of Jianpi Liqi Decoction comprehensive therapy on primary liver cancer[J]. China J Tradit Chin Med Pharma,2018,33(5):2018-2022.(in Chinese)陈晓乐，徐立涛，王鹏，等．健脾理气方综合治疗原发性肝癌患者的生存分析[J]．中华中医药杂志，2018,33(5):2018-2022.
|
|
[24] ZHOU GL,WANG YN,HUANG JH,et al. Clinical study on elemene injection combined with sorafenib in treatment of liver cancer[J]. Mod Drug Clin,2018,33(6):1466-1471.(in Chinese)周广磊，王英楠，黄景昊，等．榄香烯注射液联合索拉非尼治疗肝癌的临床研究[J]．现代药物与临床，2018,33(6):1466-1471.
|
|
[25] JIANG R. Effect of huaier ke li on patients after liver cancer embolization chemotherapy[J/CD]. J Clin Med,2017,4(63):12423,12425.(in Chinese)蒋蕊．槐耳颗粒对肝癌栓塞化疗后患者的影响探讨[J/CD]．临床医药文献电子杂志，2017,4(63):12423,12425.
|
|
[26] SUN YH,OUYANG MY,SONG S,et al. Protective effect and mechanism of tanshinone II A on hepatocellular carcinoma[J]. Clin J Med Offic,2019,47(9):895-898.(in Chinese)孙英慧，欧阳明玥，宋爽，等．丹参酮ⅡA对肝细胞癌保护作用与机制研究[J]．临床军医杂志，2019,47(9):895-898.
|
|
[27] LIU L,LI C,HAN T. Effect of composite radix sophora flavescentis injection on the proliferation of hepatocarcinoma Hep3B cells[J]. Clin J Med Offic,2018,46(9):1011-1013.(in Chinese)刘璐，李川，韩涛．复方苦参注射液对肝癌Hep3B细胞增殖影响[J]．临床军医杂志，2018,46(9):1011-1013.
|
|
[28] de BENEDETTI VM,WELSH JA,YU MC,et al. p53 mutations in hepatocellular carcinoma related to oral contraceptive use[J]. Carcinogenesis,1996,17(1):145-149.
|
|
[29] XU NF,YUAN YL,GONG L. Clinical value of the expression of estrogen receptorαin liver tissue in pathological diagnosis of liver cancer[J]. Curr Physician,2019,25(15):59-62.(in Chinese)涂宁芳，袁雅玲，龚龙．肝癌病理诊断中肝组织雌激素受体α表达的临床价值[J]．当代医学，2019,25(15):59-62.
|
|
[30] FARINATI F,SALVAGNINI M,de MARIA N,et al. Unresectable hepatocellular carcinoma:A prospective controlled trial with tamoxifen[J]. J Hepatol,1990,11(3):297-301.
|
|
[31] ZHENG TR,ZHANG QZ,XIE ZF,et al. Study of estrogen receptors in hepatocellular carcinoma and its response to antiestrogen therapy[J]. Chin J Oncol,1997,6(11):53-55.(in Chinese)郑天荣，张其忠，谢佐福，等．中晚期原发性肝癌雌激素受体与抗雌激素治疗的近期效果[J]．中华肿瘤杂志，1997,6(11):53-55.
|
|
[32] CHOW PK,TAI BC,TAN CK,et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:A multicenter randomized controlled trial[J]. Hepatology,2002,36(5):1221-1226.
|
|
[33] LLOVET JM,BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J]. Hepatology,2003,37(2):429-42.
|
DownLoad: